AI Article Synopsis

  • Epilepsy can affect visual functions, with potential changes linked to either the disease or medication side effects.
  • A study was conducted with 100 epilepsy patients on either sodium valproate or carbamazepine, examining visual functions through eye tests.
  • No significant differences in visual function were found between the two medications, but both groups showed color vision defects, suggesting possible early retinal toxicity from the medications.

Article Abstract

Objective Epilepsy is a debilitating disease. Visual function changes have been reported and may be attributed to the epileptic changes or as a result of medication side effect. Sodium valproate and carbamazepine are both first line anti-epileptic medications used in Malaysian health care. Sodium valproate inhibits glutamate and γ-aminobutyric acid (GABA) transaminase while carbamazepine acts on the sodium channel - both are an important part of the retina. This study aimed to compare the visual functions of epilepsy patients on carbamazepine or sodium valproate monotherapy. Design A cross-sectional study was conducted at a tertiary hospital between June 2016 and November 2018. Methods Patients with idiopathic epilepsy that fulfill the inclusion and exclusion criteria were recruited from the neurology clinic. They were divided into two groups and underwent complete eye examinations. Visual functions such as color vision testing, contrast sensitivity, visual field and retinal nerve fiber layer measurement were subsequently performed. Statistical analysis was done using Statistical Package for the Social Science, version 24 (SPSS Inc, Chicago, IL, USA). Results A total of 100 patients (sodium valproate: 50 patients; carbamazepine: 50 patients) were recruited for the study. There were no statistically significant changes in anatomical or visual function between the sodium valproate and carbamazepine group. However, patients from both groups displayed color vision defect in the blue and green axes. Changes in color vision could indicate early retina toxicity secondary to the medication. Although there were no visual field changes, patients recorded a slight reduction of mean deviation. Changes of mean deviation could be attributed to the side effect of medication or the disease process. Conclusions Epileptic patients taking sodium valproate or carbamazepine did not demonstrate statistically significant change in visual function.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592832PMC
http://dx.doi.org/10.7759/cureus.4553DOI Listing

Publication Analysis

Top Keywords

sodium valproate
24
visual function
16
patients sodium
12
color vision
12
patients
9
epileptic patients
8
sodium
8
valproate carbamazepine
8
visual functions
8
patients carbamazepine
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!